Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial-Reference-Cited by-同舟云学术

Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial

Published:2018-04 Issue:4 Volume:68 Page:840-842
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Øvrehus Anne L.H.,Krarup Henrik,Birkemose Inge,Holm Dorte K.,Mössner Belinda,Ernst Anja,Christensen Peer B.

Publisher

Elsevier BV

Subject

Hepatology

Reference10 articles.

1. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review;Falade-Nwulia;Ann Intern Med,2017

2. Grebely J. We know DAAs for hepatitis C work for PWID, now what? International Network for Hepatitis in Substance Users Septemeber 9th. 2017; Jersey City, USA2017.

3. Health OW. Global health sector strategy on viral hepatitis 2016–2021, 2016.

4. Modelling hepatitis C therapy–predicting effects of treatment;Perelson;Nat Rev Gastroenterol Hepatol,2015

5. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection;Foster;Gastroenterology,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients;Microbiology Spectrum;2024-09-03

2. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial;Clinical Infectious Diseases;2023-11-22

3. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients;Medicine;2023-07-14

4. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals;APMIS;2023-06-25

5. Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus;PLOS ONE;2023-01-23